Interferon_beta-1b: profile and news

Pfizer CEO Earned Nearly $16 MLN in 2005 and Chiron Confirms ... Feb 27, 2006
...agreement with Chiron to purchase or lease all assets used by Chiron in the manufacture for Schering of BETASERON® interferon beta-1b products and all ... - Financial News USA (press release),

New Survey of Neurologists Sheds Light on Trends for MS Therapy Feb 16, 2006
General Information The Image of MS and the neurologist survey are sponsored by Berlex, Inc., marketers of Betaseron® (interferon beta-1b). ... - PharmaLive.com (press release),

Schering AG: Set for Betaseron Buy-Back Boost Feb 22, 2006
Schering has announced its intention to end its supply relationship with Chiron, its US marketing partner for Betaseron (interferon beta-1b). ... - International News Service,

Clorox: Worst over for rising commodity costs Feb 24, 2006
In another announcement, Chiron said Schering AG agreed to purchase its assets used to manufacture Betaseron interferon beta-1b products to treat multiple ... - San Jose Mercury News,

Schering to buy some Chiron assets Feb 24, 2006
...said Friday that Schering AG agreed to purchase its assets used to manufacture Betaseron interferon beta-1b products to treat multiple sclerosis. ... - BusinessWeek

Schering to buy or lease all Chiron assets used to produce ... Feb 27, 2006
...joint collaboration agreement to purchase or lease all assets used by Chiron in the manufacture for Schering of MS drug Betaseron interferon beta-1b products. ... - Forbes

Chiron Confirms Proposed Purchase of BETASERON Assets by Schering ... Feb 24, 2006
...agreement with Chiron topurchase or lease all assets used by Chiron in the manufacture forSchering of BETASERON(R) interferon beta-1b products and ... - Finanzen.net,

Schering says 2005 was a 'record year Feb 20, 2006
Schering's top-selling product, the multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b) also climbed 12% in the quarter to 240 million euros, an ... - Pharma Times (subscription),

Berlex Files Application for Use of Betaseron in Patients with a ... Feb 23, 2006
...of a supplemental biologics license application (sBLA) requesting an expanded label for its multiple sclerosis (MS) therapy, Betaseron(R) (interferon beta-1b). ... - PharmaLive.com (press release),

Berlex Files Application for Use of Betaseron in Patients with a ... Feb 23, 2006
...of a supplemental biologics license application (sBLA) requesting an expanded label for its multiple sclerosis (MS) therapy, Betaseron® (interferon beta-1b). ... - Yahoo! News (press release)

Image of Multiple Sclerosis Captured Through Photographic Exhibit ... Feb 2, 2006
...and, if diagnosed, to start treatment as soon as possible." Since beginning treatment two-and-a-half years ago with Betaseron® (interferon beta-1b), one of ... - Yahoo! News (press release)

Other information

Indication
For treatment of relapsing/remitting multiple sclerosis

Pharmacology
Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.

Mechanism Of Action
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.

Drug Category
Antiviral Agents; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)

Brand Names/Synonyms
Interferon beta precursor;IFN-beta;Fibroblast interferon; Betaseron (Chiron Corp)

Dosage Forms
LIQUID;POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human interferon beta

Chemical Formula
C908H1408N246O253S6

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
BIOD00078

CAS Registry Number
96778-78-8; 145155-23-3